Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 18;66(10):e0074522.
doi: 10.1128/aac.00745-22. Epub 2022 Sep 27.

Reduced Ceftaroline Susceptibility among Invasive MRSA Infections in Children: a Clinical and Genomic Investigation

J Chase McNeil  1 , Lauren M Sommer  1 , Jesus G Vallejo  1 , Kristina G Hulten  1 , Sheldon L Kaplan  1 , Anthony R Flores  2
Affiliations

Reduced Ceftaroline Susceptibility among Invasive MRSA Infections in Children: a Clinical and Genomic Investigation

J Chase McNeil et al. Antimicrob Agents Chemother. .

Abstract

Ceftaroline represents an attractive therapy option for methicillin-resistant Staphylococcus aureus (MRSA). Little data is available, however, regarding the frequency of reduced susceptibility (RS) to ceftaroline among pediatric MRSA infections. We screened invasive MRSA isolates at a tertiary children's hospital for ceftaroline RS. Ceftaroline RS occurred in 2.9% of isolates and only among health care associated infections. Ceftaroline RS isolates were more often clindamycin-resistant. Sequencing data indicated the predominance of the CC5 lineage among ceftaroline RS isolates.

Keywords: MRSA; ceftaroline; health care associated; invasive; mecR; pediatric; resistance.

PubMed Disclaimer

Conflict of interest statement

The authors declare a conflict of interest. Ceftaroline powder was provided by Allergan through an investigator initiated research program for which J.C.M. was the PI; Allergan had no direct role in the conduct of the study or data analysis. J.C.M. receives grant funding from the Agency for Healthcare Research and Quality (AHRQ R01HS026896). J.C.M. is the local PI on a multicentre clinical trial sponsored by Nabriva Therapeutics unrelated to the work under consideration. S.L.K. and K.G.H. receive research support through Pfizer unrelated to the work under consideration. A.R.F. receives grant funding through NIAID R01AI25216, R21AI153663, R21AI142126, R21AI59059.

Similar articles

See all similar articles

Cited by

References

    1. Cannavino CR, Mendes RE, Sader HS, Farrell DJ, Critchley IA, Biek D, Le J, Skochko SM, Jones RN, Bradley JS. 2016. Evolution of ceftaroline-resistant Mrsa in a child with cystic fibrosis following repeated antibiotic exposure. Pediatr Infect Dis J 35:813–815. doi:10.1097/INF.0000000000001171. - DOI - PubMed
    1. Long SW, Olsen RJ, Mehta SC, Palzkill T, Cernoch PL, Perez KK, Musick WL, Rosato AE, Musser JM. 2014. PBP2a mutations causing high-level Ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 58:6668–6674. doi:10.1128/AAC.03622-14. - DOI - PMC - PubMed
    1. Alm RA, McLaughlin RE, Kos VN, Sader HS, Iaconis JP, Lahiri SD. 2014. Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective. J Antimicrob Chemother 69:2065–2075. doi:10.1093/jac/dku114. - DOI - PubMed
    1. Lahiri SD, Alm RA. 2016. Identification of non-PBP2a resistance mechanisms in Staphylococcus aureus after serial passage with ceftaroline: involvement of other PBPs. J Antimicrob Chemother 71:3050–3057. doi:10.1093/jac/dkw282. - DOI - PubMed
    1. Sanson MA, Macias OR, Shah BJ, Hanson B, Vega LA, Alamarat Z, Flores AR. 2019. Unexpected relationships between frequency of antimicrobial resistance, disease phenotype and emm type in group A Streptococcus. Microb Genom 5:e000316. - PMC - PubMed

Publication types